Healthcare [ 13/13 ] | Drug Manufacturers - Specialty & Generic [ 100/164 ]
NASDAQ | Common Stock
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.
The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold.
The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns.
It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies.
Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.02 Increased by 0.00% | -0.03 Increased by +33.33% |
| Feb 29, 24 | -0.00 Decreased by -107.17% | 0.01 Decreased by -143.00% |
| Nov 9, 23 | 0.02 Decreased by -45.80% | 0.01 Increased by +100.00% |
| Aug 9, 23 | 0.04 Decreased by -42.86% | 0.03 Increased by +33.33% |
| May 10, 23 | -0.02 Decreased by -319.78% | -0.02 |
| Mar 1, 23 | 0.06 Decreased by -84.62% | 0.05 Increased by +20.00% |
| Nov 9, 22 | 0.04 Decreased by -63.10% | 0.06 Decreased by -38.50% |
| Aug 9, 22 | 0.07 Decreased by -53.33% | 0.08 Decreased by -12.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 109.98 M Increased by +2.17% | -2.10 M Increased by +29.27% | Decreased by -1.91% Increased by +30.77% |
| Dec 31, 23 | 99.65 M Decreased by -13.73% | -568.00 K Decreased by -107.59% | Decreased by -0.57% Decreased by -108.80% |
| Sep 30, 23 | 108.53 M Decreased by -7.13% | 12.11 M Increased by +5.53 K% | Increased by +11.16% Increased by +5.96 K% |
| Jun 30, 23 | 117.32 M Decreased by -3.36% | 5.32 M Decreased by -39.20% | Increased by +4.53% Decreased by -37.09% |
| Mar 31, 23 | 107.64 M Increased by +9.71% | -2.97 M Decreased by -3.51 K% | Decreased by -2.76% Decreased by -3.21 K% |
| Dec 31, 22 | 115.52 M Decreased by -10.14% | 7.49 M Decreased by -85.52% | Increased by +6.48% Decreased by -83.88% |
| Sep 30, 22 | 116.86 M Increased by +2.73% | 215.00 K Decreased by -98.29% | Increased by +0.18% Decreased by -98.34% |
| Jun 30, 22 | 121.40 M Decreased by -1.46% | 8.74 M Decreased by -57.73% | Increased by +7.20% Decreased by -57.11% |